All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells

PURPOSE: Pharmacological inhibition of mutant isocitrate dehydrogenase (IDH) reduces R-2-hydroxyglutarate (2-HG) levels and restores cellular differentiation in vivo and in vitro. The IDH2 inhibitor enasidenib (AG-221) has been approved by the FDA as a first-in-class inhibitor for the treatment of r...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Yonsei Med J
Egile Nagusiak: Kim, Yundeok, Jeung, Hoi-Kyung, Cheong, June-Won, Song, Jaewoo, Bae, Soo Han, Lee, Jong In, Min, Yoo Hong
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Yonsei University College of Medicine 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7471081/
https://ncbi.nlm.nih.gov/pubmed/32882760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2020.61.9.762
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak